New hope for rare blistering disease: rituximab vs standard therapy
NCT ID NCT03295383
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two drugs, rituximab and cyclophosphamide, in 92 adults with severe mucous membrane pemphigoid, a rare autoimmune disease that causes painful blisters and scarring on mucous membranes. The goal is to see which treatment is safer and more effective at controlling the disease and preventing complications like blindness or breathing problems. Participants receive either drug plus a placebo, and doctors track remission rates and side effects over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE FORMS OF MUCOUS MEMBRANE PEMPHIGOID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
APHM La Timone
Marseille, France
-
APHP Avicennes
Paris, France
-
APHP Bichat
Paris, France
-
APHP Cochin
Paris, France
-
APHP Henri Mondor
Paris, France
-
APHP Pitié Salpétrière
Paris, France
-
APHP Saint-Louis
Paris, France
-
Brest University Hospital
Brest, France
-
CH Argenteuil
Argenteuil, France
-
CH Le Mans
Le Mans, France
-
CH Quimper
Quimper, France
-
CHU Amiens
Amiens, France
-
CHU Angers
Angers, France
-
CHU Bordeaux
Bordeaux, France
-
CHU Caen
Caen, France
-
CHU Clermont Ferrand
Clermont-Ferrand, France
-
CHU Dijon
Dijon, France
-
CHU Lille
Lille, France
-
CHU Montpellier
Montpellier, France
-
CHU Nantes
Nantes, France
-
CHU Nice
Nice, France
-
CHU Rennes
Rennes, France
-
CHU Tours
Tours, France
-
CHU de Limoges
Limoges, France
-
CHU de Reims
Reims, France
-
CHU saint-Etienne
Saint-Etienne, France
-
HCL
Lyon, France